Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Other Non-Current Assets (2023 - 2025)

CG Oncology (CGON) has disclosed Other Non-Current Assets for 3 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets rose 1685.11% year-over-year to $1.7 million, compared with a TTM value of $1.7 million through Dec 2025, up 1685.11%, and an annual FY2025 reading of $1.7 million, up 1685.11% over the prior year.
  • Other Non-Current Assets was $1.7 million for Q4 2025 at CG Oncology, up from $114000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $4.7 million in Q4 2023 and bottomed at $53000.0 in Q1 2024.
  • Average Other Non-Current Assets over 3 years is $861111.1, with a median of $114000.0 recorded in 2025.
  • The sharpest move saw Other Non-Current Assets tumbled 97.99% in 2024, then soared 1685.11% in 2025.
  • Year by year, Other Non-Current Assets stood at $4.7 million in 2023, then crashed by 97.99% to $94000.0 in 2024, then skyrocketed by 1685.11% to $1.7 million in 2025.
  • Business Quant data shows Other Non-Current Assets for CGON at $1.7 million in Q4 2025, $114000.0 in Q3 2025, and $522000.0 in Q2 2025.